Please Wait.....
Report
Global Meningococcal Vaccines Market Report and Forecast 2023-2031
Market Report I 2023-05-06 I 147 Pages I EMR Inc.
Global Meningococcal Vaccines Market Report and Forecast 2023-2031
Global Meningococcal Vaccines Market Outlook:
The global meningococcal vaccines market value was USD 3.45 billion in 2022, driven by the increasing prevalence of meningococcal disease across the globe. The market size is anticipated to grow at a CAGR of 6.8% during the forecast period of 2023-2031 to achieve a value of USD 6.24 billion by 2031.
Introduction
Meningococcal vaccines are designed to protect against meningococcal disease, which is caused by the bacterium Neisseria meningitidis. Meningococcal disease can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (bloodstream infection), both of which can be life-threatening. Meningococcal vaccines stimulate the immune system to produce an immune response against the bacteria, providing protection against the disease.
Key Trends in the Meningococcal Vaccines Market
Some key trends involved in the meningococcal vaccines market are as follows:
- Increasing Global Immunization Efforts: There is a growing emphasis on immunization programs worldwide to combat meningococcal disease. Governments and healthcare organizations are promoting routine immunization of infants and adolescents to reduce the incidence of the disease. This trend is driven by the recognition of the public health impact of meningococcal infections and the availability of effective vaccines.
- Expansion of Vaccine Coverage: In recent years, there has been an expansion in the number of countries including meningococcal vaccines in their national immunization schedules. This includes both developed and developing countries, with an aim to protect vulnerable populations and prevent outbreaks. The focus is on providing access to vaccines to those at highest risk, such as infants, adolescents, and individuals living in high-risk areas or participating in certain activities (e.g., travel, military service).
- Advancements in Vaccine Technology: The development of new meningococcal vaccines and advancements in vaccine technology are driving the market. These include the introduction of conjugate vaccines, which offer broader protection against multiple serogroups of Neisseria meningitidis. Conjugate vaccines have demonstrated enhanced immunogenicity and longer-lasting protection compared to earlier generations of vaccines. Additionally, efforts are underway to develop vaccines that provide protection against emerging serogroups and to improve the efficacy and duration of immune response.
- Focus on Serogroup B Vaccines: Serogroup B of Neisseria meningitidis has historically posed a challenge for vaccine development due to its complex polysaccharide structure. However, there have been significant advancements in the development of serogroup B vaccines, including the use of novel approaches such as recombinant protein-based vaccines and outer membrane vesicle vaccines. This has opened up new possibilities for providing protection against this particular serogroup.
Meningococcal Vaccines Market Segmentations
Market Breakup by Type
- Mono Vaccines
- Combination Vaccines
Market Breakup by Age Group
- Infants
- Childrens
- Adults
Market Breakup by Brand
- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Meningococcal Vaccines Market Scenario
The global market for meningococcal vaccines is experiencing significant growth due to the increasing incidence of meningococcal disease and the growing awareness about the importance of vaccination. Meningococcal disease is a serious public health concern, and the demand for effective vaccines is driving the market growth.
Several factors contribute to the market expansion. First, governments and healthcare organizations are implementing robust immunization programs to prevent meningococcal infections. This includes the incorporation of meningococcal vaccines into national immunization schedules and the promotion of routine vaccination for at-risk populations. This focus on immunization is creating a favourable market environment for meningococcal vaccines.
Geographically, the market for meningococcal vaccines is witnessing growth across regions. Developed countries have well-established immunization programs, while developing countries are expanding their vaccination efforts to combat the disease burden. Additionally, travel-related vaccinations and initiatives aimed at preventing outbreaks in high-risk areas contribute to the market growth.
Meningococcal Vaccines Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Johnson & Johnson Private Limited
- Mylan N.V.
- Sun Pharmaceutical Industries Limited
- Sanofi S.A.
- Merck & Co., Inc.
- GSK plc.
- Novartis AG
- AbbVie Inc.
- Fresenius Kabi AG
- Amneal Pharmaceuticals LLC.
- Pfizer Inc.
- Serum Institute of India Pvt. Ltd.
- Incepta Pharmaceuticals Ltd.
- Walvax Biotechnology Co., Ltd.
- Bio-Manguinhos
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Meningococcal Vaccines Market Overview
3.1 Global Meningococcal Vaccines Market Historical Value (2016-2022)
3.2 Global Meningococcal Vaccines Market Forecast Value (2023-2031)
4 Global Meningococcal Vaccines Market Landscape
4.1 Global Meningococcal Vaccines Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Meningococcal Vaccines Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by End User
4.2.3 Analysis by Major Regions
5 Global Meningococcal Vaccines Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Meningococcal Vaccines Market Segmentation
6.1 Global Meningococcal Vaccines Market by Type
6.1.1 Market Overview
6.1.2 Mono Vaccines
6.1.3 Combination Vaccines
6.2 Global Meningococcal Vaccines Market by Age Group
6.2.1 Market Overview
6.2.2 Infants
6.2.3 Childrens
6.2.4 Adults
6.3 Global Meningococcal Vaccines Market by Brand
6.3.1 Market Overview
6.3.2 Menactra
6.3.3 Menveo
6.3.4 Nimenrix
6.3.5 Trumenba
6.3.6 Bexsero
6.3.7 Others
6.4 Global Meningococcal Vaccines Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.4.4 Specialty Clinics
6.4.5 Others
6.5 Global Meningococcal Vaccines Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Online Pharmacy
6.5.4 Retail Pharmacy
6.5.5 Others
6.6 Global Meningococcal Vaccines Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Meningococcal Vaccines Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Meningococcal Vaccines Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Meningococcal Vaccines Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Meningococcal Vaccines Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Meningococcal Vaccines Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Johnson & Johnson Private Limited
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Mylan N.V.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Sun Pharmaceutical Industries Limited
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sanofi S.A.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Merck & Co., Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 GSK plc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 AbbVie Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Fresenius Kabi AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Amneal Pharmaceuticals LLC.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Pfizer Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Serum Institute of India Pvt. Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Incepta Pharmaceuticals Ltd.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Walvax Biotechnology Co., Ltd.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Bio-Manguinhos
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global Meningococcal Vaccines Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security